Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan

PRODUCT CENTER Innovent has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, 4 assets in Phase III or pivotal clinical trials, and additional 15 molecules in or close to clinical trials. TYVYT® has been the only PD-1 inhibitor included in the NRDL since 2019. Sintilimab, an innovative biological drug that independently developed by Innovent Biologics, Inc. (Suzhou), is a fully humanized IgG4 monoclonal antibody. It can specifically bind to PD-1 expressed on the surface of T cells to block this immune escape pathway, reactivate T cells, and release cytokines to kill tumor cells.Sintilimab, an innovative biological drug that independently developed by Innovent Biologics, Inc. (Suzhou), is a fully humanized IgG4 monoclonal antibody. It can specifically bind to PD-1 expressed on the surface of T cells to block this immune escape pathway, reactivate T cells, and release cytokines to kill tumor cells.

Takeda and Arrowhead Pharmaceuticals team up in rare liver disease

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines

Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

Thu October 8, 2020 7:30 AM|Business Wire|About: ARWR, TAK

− Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD

− Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M

− Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda (TKPHF) and Arrowhead under a 50/50 profit-sharing structure

− Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.

− Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET

OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (ARWR)

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005340/en/

For more information, visit https://www.takeda.com.

https://www.takeda.com/investors/

For more information, please visit www.arrowheadpharma.com

https://seekingalpha.com/symbol/ARWR

Pipeline

Novel Drugs to
Treat Intractable Diseases

https://arrowheadpharma.com/pipeline/

Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease

October 8, 2020 Osaka, JAPAN, and Pasadena, CALIF.

Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD
Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M
Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda and Arrowhead under a 50/50 profit-sharing structure
Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.
Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)

https://www.takeda.com/newsroom/newsreleases/2020/takeda-and-arrowhead-collaborate-to-co-develop-and-co-commercialize-aro-aat-foralpha-1-antitrypsin-associated-liver-disease/

Pipeline Novel Drugs to Treat Intractable Diseases

BiotechVortex™

Bristol Myers Squibb to acquire Myokardia for $13.1B in cash

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Mon October 5, 2020 6:30 AM|Business Wire|About: BMY, MYOK

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval

Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise

Expected to be Accretive to Non-GAAP Earnings Starting in 2023

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (MYOK)

For more information about Bristol Myers Squibb, visit us at BMS.com

www.myokardia.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005381/en/

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

10/05/2020CATEGORY:

Corporate/Financial News

Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval

Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise

Expected to be Accretive to Non-GAAP Earnings Starting in 2023

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020.

https://news.bms.com/news/corporate-financial/2020/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash/default.aspx

https://seekingalpha.com/symbol/MYOK

http://www.cstonepharma.com/en/

MyoKardia

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

Tue September 29, 2020 11:22 PM|Business Wire|About: LGND, PFE

Pfizer (PFE) to invest $200 million in CStone shares and license CStone’s late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China
CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties
CStone and Pfizer to develop and commercialize additional late-stage oncology therapies in Greater China

SUZHOU, China--(BUSINESS WIRE)-- CStone Pharmaceuticals (CSPHF) (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong") (both of which are subsidiaries of Pfizer Inc.)

For more information about CStone, please visit: www.cstonepharma.com.

For more information, please visit www.pfizer.com.cn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200929006175/en/

https://seekingalpha.com/symbol/CSPHF

CSTONE PHARMACEUTICALS - B (2616)

https://www.hkex.com.hk/Market-Data/Securities-Prices/Equities/Equities-Quote?sym=2616&sc_lang=en

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China Times：2020.09.30 Author：CStone Pfizer to invest $200 million in CStone shares and license CStone’s late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties CStone and Pfizer to develop and commercialize additional late-stage oncology therapies in Greater China (SUZHOU, China, Sept 30, 2020) CStone Pharmaceuticals (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong") (both of which are subsidiaries of Pfizer Inc. (NYSE: PFE)) announced today the formation of a strategic collaboration that encompasses a $200 million equity investment by Pfizer Hong Kong in CStone, collaboration between CStone and Pfizer Investment for the development and commercialization of CStone’s sugemalimab (CS1001, PD-L1 antibody) in mainland China, and a framework between CStone and Pfizer Investment to bring additional oncology assets to the Greater China market.

Roche doubles down on promising inflammation field with Inflazome buy

CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China

Roche doubles down on promising inflammation field with Inflazome buy

Inflazome Announces Acquisition by Roche

Mon September 21, 2020 2:00 AM|Business Wire|About: RHHBY

Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
Acquisition of Inflazome gives Roche (RHHBY) full rights to the Inflazome portfolio
Activation of the NLRP3 inflammasome in the body is implicated in many diseases caused by chronic, uncontrolled inflammation
Inflazome shareholders received €380 million upfront, and are eligible to receive additional milestone payments

DUBLIN & CAMBRIDGE, England--(BUSINESS WIRE)

View source version on businesswire.com: https://www.businesswire.com/news/home/20200920005066/en/

https://www.cell.com/fulltext/S0092-8674%2810%2900075-9

https://seekingalpha.com/news/3616633-roche-doubles-down-on-promising-inflammation-field-inflazome-buy

Roche doubles down on promising inflammation field with Inflazome buy

Sep. 26, 2020 12:30 AM ET|About: Roche Holding AG (RHHBY)|By: Douglas W. House, SA News Editor

Biotech Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field by Nick Paul Taylor | Sep 21, 2020 5:38am

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Roche doubles down on promising inflammation field with Inflazome buy

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease

Wed September 23, 2020 2:00 AM|Business Wire|About: PFE

PARIS & NEW YORK--(BUSINESS WIRE)-- Vivet Therapeutics

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005790/en/

Please visit us on www.vivet-therapeutics.com

PFIZER SECURES EXCLUSIVE OPTION TO ACQUIRE GENE THERAPY COMPANY VIVET THERAPEUTICS

Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease

Pfizer acquires 15% ownership stake in Vivet

Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics (“Vivet”),

https://www.vivet-therapeutics.com/en/news-events/latest/pfizer-secures-exclusive-option-to-acquire-gene-therapy-company-vivet-therapeutics

https://seekingalpha.com/news/3614927-vaccinex-partners-merck-in-cancer

Product Pipeline

Pepinemab in Combination with KEYTRUDA

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Thu September 17, 2020 8:00 AM|GlobeNewswire|About: VCNX

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX)

http://www.vaccinex.com/

Vaccinex partners with Merck in cancer

Sep. 17, 2020 8:31 AM ET|About: Vaccinex, Inc. (VCNX)|By: Mamta Mayani, SA News Editor .com/news/3614927-vaccinex-partners-merck-in-cancer

http://www.vaccinex.com/pipeline/pepinemab-immuno-oncology/

https://seekingalpha.com/symbol/VCNX

Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX)

http://ir.vaccinex.com/news-releases/news-release-details/vaccinex-announces-clinical-collaboration-merck-evaluate

Pepinemab Immuno-Oncology First in class, anti-SEMA4D immunotherapy for cancer.

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

Thu September 17, 2020 8:30 AM|Accesswire|About: DYAI

LIANYUNGANG, CHINA and JUPITER, FL / ACCESSWIRE / September 17, 2020 / Dyadic International, Inc. (DYAI) ("Dyadic" or the "Company") (NASDAQ:DYAI)

Please visit Dyadic's website at http://www.dyadic.com for additional information

please visit http://www.hrs.com.cn/index.html.

http://www.hrs.com.cn/index.html

https://www.hengruitx.com/

Dyadic teams up with Jiangsu Hengrui for biologic drug development

Sep. 17, 2020 9:05 AM ET|About: Dyadic International, Inc. (DYAI)|By: Mamta Mayani, SA News Editor

https://seekingalpha.com/news/3614955-dyadic-teams-up-jiangsu-hengrui-for-biologic-drug-development

http://www.dyadic.com/.

https://seekingalpha.com/symbol/DYAI

https://www.hengruitx.com/rd.html#Htipipe

HTI U.S. / GLOBAL CLINICAL STUDIES

BiotechVortex™

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Thu September 17, 2020 6:30 AM|PR Newswire|About: AMGN, LLYPR Newswire

INDIANAPOLIS and THOUSAND OAKS, Calif., Sept. 17, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) and Amgen (AMGN)

For more information, visit www.amgen.com

To learn more about Lilly, please visit us at lilly.com

https://www.prnewswire.com/news-releases/lilly-and-amgen-announce-manufacturing-collaboration-for-covid-19-antibody-therapies-301132807.html

https://seekingalpha.com/symbol/AMGN

https://www.lilly.com/discovery/clinical-development-pipeline

Medicines in Development Molecule & Potential Indication Data as of July 28, 2020 Interested in Lilly clinical trials? Learn more at LillyTrialGuide.com

Takeda Opens New R&D Cell Therapy Manufacturing Facility

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs

Tue September 15, 2020 7:30 AM|Business Wire|About: TAK

cGMP Facility Builds Takeda’s Leadership Capabilities in Cell Therapy and Increases its Capacity to Supply Innovative Cell Therapies for Global Clinical Trials
Five Collaborative Oncology Cell Therapy Programs Expected to be in Clinical Development by the End of FY2021

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK)

https://www.takeda.com/

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005224/en/

For more information, visit https://www.takeda.com.

https://seekingalpha.com/symbol/TAK

Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs September 15, 2020 Osaka, JAPAN cGMP Facility Builds Takeda’s Leadership Capabilities in Cell Therapy and Increases its Capacity to Supply Innovative Cell Therapies for Global Clinical Trials Five Collaborative Oncology Cell Therapy Programs Expected to be in Clinical Development by the End of FY2021 Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK)

Moderna builds footprint outside U.S. in Switzerland

Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

Moderna builds footprint outside U.S. in Switzerland

Moderna Announces First Commercial Organization Outside North America in Switzerland

Wed September 16, 2020 5:00 AM|Business Wire|About: MRNA

Dan Staner appointed as Vice President and Managing Director, Switzerland

Reinforces Moderna’s commitment to Europe

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (MRNA), (Nasdaq: MRNA)

To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005315/en/

https://seekingalpha.com/symbol/MRNA

Moderna builds footprint outside U.S. in Switzerland

https://seekingalpha.com/news/3614438-moderna-builds-footprint-outside-u-s-in-switzerland

Moderna Announces First Commercial Organization Outside North America in Switzerland September 16, 2020 at 5:00 AM EDT PDF Version Dan Staner appointed as Vice President and Managing Director, Switzerland Reinforces Moderna’s commitment to Europe CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 16, 2020-- Moderna, Inc., (Nasdaq: MRNA)

Seattle Genetics teams up with Merck in cancer

SpringWorks teams up with Janssen in multiple myeloma study

Moderna builds footprint outside U.S. in Switzerland

Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations

Mon September 14, 2020 6:45 AM|Business Wire|About: MRK, SGEN

Companies to Co-Develop and Co-Commercialize Seattle Genetics’ Antibody-Drug Conjugate Ladiratuzumab Vedotin Globally; Merck (MRK) to Acquire $1 Billion Equity Stake in Seattle Genetics Common Stock

Companies Enter Exclusive License and Co-Development Agreement to Accelerate Global Reach of TUKYSA for HER2-Postive Cancers in Regions Outside the United States, Canada and Europe

Seattle Genetics (SGEN) to Host Conference Call Today at 9:00 a.m. ET

BOTHELL, Wash. & KENILWORTH, N.J.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck, known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200914005237/en/

https://seekingalpha.com/symbol/MRK

https://seekingalpha.com/symbol/SGEN

Seattle Genetics teams up with Merck in cancer

https://seekingalpha.com/news/3613576-seattle-genetics-teams-up-merck-in-cancer

Seattle Genetics website at www.seattlegenetics.com

https://www.seattlegenetics.com/pipeline/tisotumab-vedotin

For more information, visit www.merck.com

For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials.

Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations 09/14/2020 Companies to Co-Develop and Co-Commercialize Seattle Genetics’ Antibody-Drug Conjugate Ladiratuzumab Vedotin Globally; Merck to Acquire $1 Billion Equity Stake in Seattle Genetics Common Stock Companies Enter Exclusive License and Co-Development Agreement to Accelerate Global Reach of TUKYSA for HER2-Postive Cancers in Regions Outside the United States, Canada and Europe Seattle Genetics to Host Conference Call Today at 9:00 a.m. ET BOTHELL, Wash. & KENILWORTH, N.J.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations.

SpringWorks teams up with Janssen in multiple myeloma study

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

Mon September 14, 2020 6:30 AM|GlobeNewswire|About: SWTXGlobeNewswire

STAMFORD, Conn., Sept. 14, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX)

SpringWorks teams up with Janssen in multiple myeloma study

https://seekingalpha.com/news/3613550-springworks-teams-up-janssen-in-multiple-myeloma-study

https://seekingalpha.com/symbol/SWTX

https://seekingalpha.com/symbol/JNJ

For more information, please visit www.springworkstx.com

https://www.springworkstx.com/pipeline/nirogacestat/

SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma

September 14, 2020 at 6:30 AM EDTPDF Version

Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities

STAMFORD, Conn., Sept. 14, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX

https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-announces-clinical-collaboration

Nirogacestat (Gamma Secretase Inhibitor) Nirogacestat is an oral, selective, small molecule, gamma secretase inhibitor (GSI) in Phase 3 clinical development for patients with desmoid tumors. Gamma secretase is a protease complex that cleaves, or divides, multiple transmembrane protein complexes, including Notch, which, when dysregulated, can play a role in activating pathways that contribute to desmoid tumor growth.

Gilead nears deal to buy cancer drug maker for $20bn

SpringWorks teams up with Janssen in multiple myeloma study

Gilead nears $20B-plus deal to buy Immunomedics - WSJ

Sep. 12, 2020 3:31 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Carl Surran, SA News Editor

Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion

Biotech drugmaker has a market value of roughly $10 billion

By Cara Lombardo and Jonathan D. RockoffUpdated Sept. 12, 2020 3:31 pm ET

https://www.wsj.com/articles/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-11599936777

https://www.bloomberg.com/news/articles/2020-09-13/gilead-said-to-near-immunomedics-bid-worth-more-than-20-billion?srnd=deals

https://www.gilead.com/

Gilead to buy Immunomedics for $21B, bolstering its cancer arsenal

Sep. 13, 2020 4:32 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Liz Kiesche, SA News Editor

https://seekingalpha.com/news/3613503-gilead-to-buy-immunomedics-for-21b-bolstering-cancer-arsenal

September 13, 2020

Gilead Sciences to Acquire Immunomedics

-- Gilead Adds TrodelvyTM, First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors --

-- Acquisition Transforms Gilead’s Portfolio with First-in-Class Commercial Product with Significant Revenue and Best-in-Class Potential --

-- Trodelvy will Accelerate Gilead’s Emerging and Complementary Oncology Pipeline, Building on Agreements Executed Earlier This Year --

-- Immunomedics to Present Latest Clinical Findings on Trodelvy at European Society for Medical Oncology Virtual Congress 2020 This Coming Week --

FOSTER CITY, Calif. & MORRIS PLAINS, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU)

https://www.gilead.com/news-and-press/press-room/press-releases/2020/9/gilead-sciences-to-acquire-immunomedics

Gilead nears deal to buy cancer drug maker for $20bn Offer is worth close to double New Jersey-based Immunomedics’ market value James Fontanella-Khan, Ortenca Aliaj and Hannah Kuchler SEPTEMBER 12 2020

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

Fri September 4, 2020 7:00 AM|PR Newswire|About: ABBV, IMAB

I-Mab to receive upfront payment of USD180 million

Potential to explore combination therapies with I-Mab's lemzoparlimab and AbbVie's venetoclax (Venclexta®)

I-Mab to host call for investors on September 4 at 8:00 am ET

PR Newswire

NORTH CHICAGO, Illinois and SHANGHAI, China, Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (IMAB)

For more information, please visit http://ir.i-mabbiopharma.com

For more information about AbbVie, please visit us at www.abbvie.com.

https://www.prnewswire.com/news-releases/abbvie-and-i-mab-enter-into-global-strategic-partnership-for-differentiated-immuno-oncology-therapy-301124424.html

https://seekingalpha.com/symbol/IMAB

https://seekingalpha.com/symbol/ABBV

https://www.i-mabbiopharma.com/en/Pipeline.aspx

AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

AbbVie and I-Mab to collaborate on development and commercialization of I-Mab’s highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)

I-Mab to receive upfront payment of USD180 million

Potential to explore combination therapies with I-Mab’s lemzoparlimab and AbbVie’s venetoclax (Venclexta®)

I-Mab to host call for investors on September 4 at 8:00am ET

NORTH CHICAGO, Illinois and SHANGHAI, China, September 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (Nasdaq: IMAB)

https://www.i-mabbiopharma.com/en/article-564.aspx

Pipeline Strategy and Progress

ACE2-Fc is a recombinant protein

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic

Fri August 28, 2020 7:15 AM|GlobeNewswire|About: IBIOGlobeNewswire

NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (IBIO) (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology innovator and biologics contract manufacturing organization, today announced that it has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. (“Planet”) for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc.

https://www.ibioinc.com/therapeutics-and-vaccines/human-and-animal-health-internal-pipeline

https://www.planetbiotechnology.com/products.html

https://ir.ibioinc.com/press-releases/detail/134/ibio-and-planet-biotechnology-enter-into-exclusive

For more information, visit www.ibioinc.com.

https://seekingalpha.com/symbol/IBIO

Human and Animal Health Internal Pipeline

AbbVie teams up with Harvard in viral infection research

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

AbbVie teams up with Harvard in viral infection research

August 25, 2020

AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases

NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Aug. 25, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Harvard University

AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases

Tue August 25, 2020 8:00 AM|PR Newswire|About: ABBV

NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Aug. 25, 2020 /PRNewswire/ -- AbbVie (ABBV) and Harvard University today announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS)

https://hms.harvard.edu/

For more information about AbbVie, please visit us at www.abbvie.com.

For more information, please visit https://otd.harvard.edu.

View original content:http://www.prnewswire.com/news-releases/abbvie-harvard-university-form-research-alliance-to-address-emergent-viral-diseases-301117726.html

AbbVie teams up with Harvard in viral infection research

Aug. 25, 2020 8:39 AM ET|About: AbbVie Inc. (ABBV)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3608508-abbvie-teams-up-harvard-in-viral-infection-research

https://news.abbvie.com/news/press-releases/abbvie-harvard-university-form-research-alliance-to-address-emergent-viral-diseases.htm

https://seekingalpha.com/symbol/ABBV

Joining Forces Harvard University, AbbVie form research alliance to address emergent viral diseases August 25, 2020 Research

Bristol-Myers Squibb to acquire protein engineer Forbius

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

AbbVie teams up with Harvard in viral infection research

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio

Mon August 24, 2020 6:59 AM|Business Wire|About: BMY

Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis

NEW YORK & MONTREAL--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company

https://www.bms.com/

https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-enters-agreement-acquire-forbius-adding-l

View source version on businesswire.com: https://www.businesswire.com/news/home/20200824005159/en/

Bristol-Myers Squibb to acquire protein engineer Forbius

Aug. 24, 2020 7:12 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3608089-bristol-myers-squibb-to-acquire-protein-engineer-forbius

https://forbius.com/#pipeline

Novel biologics
for treatment of
fibrosis & cancer

https://forbius.com/

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis CATEGORY: CORPORATE/FINANCIAL NEWS MONDAY, AUGUST 24, 2020 6:59 AM EDT NEW YORK & MONTREAL--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases,

Merck finds London site for £1B research, business hub

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

Merck finds London site for £1B research, business hub

Aug. 18, 2020 3:52 AM ET|About: Merck & Co., Inc. (MRK)|By: Liz Kiesche, SA News Editor

Merck to build £1B London R&D hub for its first ex-U.S. early research center

by Ben Adams | Aug 18, 2020 4:23am

https://www.fiercebiotech.com/biotech/merck-to-build-ps1-billion-london-r-d-hub-for-its-first-ex-u-s-early-research-center

“We currently view the U.K. as a world leader in developing science, driven by the long-term emphasis on building a strong research and development infrastructure,” said David Peacock, MSD managing director for the U.K. and Ireland, speaking to the Financial Times.

Our pipeline at a glance Updated July 31, 2020. Our pipeline provides an overview of our late-stage clinical development programs and is updated quarterly.

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

Wed August 12, 2020 8:00 AM|Accesswire

RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (HBPC) (TSX:HBP)

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

Wednesday, August 12, 2020 8:00 AM

RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (TSX:HBP)

https://www.accesswire.com/601224/Helix-BioPharma-Corp-and-Moffitt-Cancer-Center-Extend-Immunotherapy-Collaboration

https://www.helixbiopharma.com/

https://moffitt.org/

https://www.helixbiopharma.com/pipeline/

https://seekingalpha.com/symbol/HBPCF

12 August 2020

Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration

RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP)

https://www.helixbiopharma.com/helix-biopharma-corp-and-moffitt-cancer-center-extend-immunotherapy-collaboration/

DOS47 Drug Candidates Our most advanced Tumor Defence Breaker L-DOS47 is currently in clinical trials for the treatment of small cell lung cancer (NSCLC) and pancreatic cancer. A second DOS47 candidate, known as V-DOS47, targets the vascular epithelial growth factor receptor 2 and is at preclinical development.

BiotechVortex™

Sarepta Therapeutics and University of Florida Announce Collaboration

Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases

Tue August 11, 2020 8:30 AM|GlobeNewswire|About: SRPT

CAMBRIDGE, Mass. and GAINESVILLE, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics Inc. (SRPT), the leader in precision genetic medicine for rare diseases, and the University of Florida today announced a strategic collaboration to enable cutting-edge research for novel genetic medicines.

http://www.ufl.edu/

please visit www.sarepta.com

https://www.sarepta.com/products-pipeline

https://seekingalpha.com/symbol/SRPT

At Sarepta, we are working with urgency to develop breakthrough therapies to treat genetic diseases. Currently, we have more than 40 investigational therapies in various stages of development—many already in late-stage clinical trials. In many cases, development is being accelerated by our gene therapy engine, which potentially provides a more efficient model for drug design.

Zhongchao Inc. Renews Contract with Johnson & Johnson (China) Limited

Sarepta Therapeutics and University of Florida Announce Collaboration

Zhongchao Inc. Renews Contract with Johnson & Johnson (China) Limited, Extending the Cooperation since 2017

Tue August 4, 2020 7:12 AM|PR Newswire|About: ZCMD

SHANGHAI, Aug. 4, 2020 /PRNewswire/ -- Zhongchao Inc. (ZCMD)

More information about the Company can be found at its investor relations website at http://izcmd.com.

https://www.prnewswire.com/news-releases/zhongchao-inc-renews-contract-with-johnson--johnson-china-limited-extending-the-cooperation-since-2017-301105575.html

https://seekingalpha.com/symbol/ZCMD

DealsSiemens Healthineers to Buy U.S. Varian Medical for $16 Billion Cash

http://www.mdmooc.org/

"MDMOOC" platform

Siemens Healthineers to Buy U.S. Varian Medical for $16 Billion Cash

Sarepta Therapeutics and University of Florida Announce Collaboration

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab

BUSINESS NEWSAUGUST 2, 2020 / 4:04 AM / UPDATED AN HOUR AGO

Siemens Healthineers expands into cancer care with $16.4 billion deal for Varian

Jörn Poltz, Douglas Busvine

4 MIN READ

MUNICH/BERLIN (Reuters)

https://www.reuters.com/article/us-varian-med-syst-m-a-siemens-health-st/siemens-healthineers-to-acquire-varian-for-164-billion-idUSKBN24Y08W

Siemens Healthineers to Buy Varian Medical for $16.4 Billion

Deal will create a leader in the area of cancer therapy

By Tom FairlessUpdated Aug. 2, 2020 8:37 am ET

https://www.wsj.com/articles/siemens-healthineers-to-buy-varian-medical-for-16-4-billion-11596371354

https://www.varian.com/

https://seekingalpha.com/symbol/VAR

https://www.siemens-healthineers.com/en-us/

Siemens Healthineers Said to Near $15 Billion Purchase of Varian

Ed Hammond and Nabila Ahmed, Bloomberg News

https://www.bnnbloomberg.ca/siemens-healthineers-said-to-near-15-billion-purchase-of-varian-1.1474159

Siemens Healthineers near $15B deal for Varian - Bloomberg

Aug. 1, 2020 9:24 PM ET|About: Siemens Healthineers AG (SEMHF)|By: Carl Surran, SA News Editor

https://seekingalpha.com/news/3598683-siemens-healthineers-near-15b-deal-for-varian-bloomberg

https://seekingalpha.com/symbol/SEMHF

Intelligent Cancer Care™ Everyone fighting cancer shares the same goal—beating it. Together, we can lead a more intelligent fight and realize our vision of a world without fear of cancer.

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma

Fri July 31, 2020 2:00 AM|GlobeNewswire|About: BNTX

BioNTech (NTGN) and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockade
Combines two immunotherapies with complementary mechanisms of action with the aim to accelerate the path to market approval in melanoma if the trial is successful
Development costs for the clinical trial to be shared equally with each company retaining full commercial rights to their respective product candidates

MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced a strategic collaboration with Regeneron

https://biontech.de/

For more information, please visit www.bioNTech.de

https://seekingalpha.com/symbol/BNTX

https://seekingalpha.com/symbol/REGN

https://www.libtayo.com/

clinical trial evaluating the combination of PD-1 inhibitor Libtayo (cemiplimab) and the latter's BNT111 FixVac candidate for the second-line treatment of patients with advanced cutaneous melanoma

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma

Sangamo teams up with Novartis in neurodevelopmental disorders

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab

Sangamo teams up with Novartis in neurodevelopmental disorders

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Thu July 30, 2020 7:00 AM|Business Wire|About: SGMO

- Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability

- Sangamo will receive a $75M upfront licensing fee and is eligible to receive up to $720M in potential milestones, as well as royalties on potential net commercial sales

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (SGMO)

www.sangamo.com.

https://www.businesswire.com/news/home/20200730005166/en/

https://www.sangamo.com/pipeline

https://seekingalpha.com/symbol/SGMO

https://seekingalpha.com/symbol/NVS

https://seekingalpha.com/news/3597652-sangamo-teams-up-novartis-in-neurodevelopmental-disorders

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

July 30, 2020 at 7:00 AM EDTDownload PDF

- Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability

- Sangamo will receive a $75M upfront licensing fee and is eligible to receive up to $720M in potential milestones, as well as royalties on potential net commercial sales

BRISBANE, Calif.--(BUSINESS WIRE)--Jul. 30, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO)

https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-global-collaboration-novartis-develop-genomic

THERAPEUTIC PROGRAMS UNDER DEVELOPMENT

Elunate® (fruquintinib capsules)

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab

Sangamo teams up with Novartis in neurodevelopmental disorders

Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China

Tue July 28, 2020 2:00 AM|GlobeNewswire|About: HCM

HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (HCM) (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company

https://www.chi-med.com/

in June 2018 (clinicaltrials.gov identifier: NCT02314819).

(clinicaltrials.gov identifier: NCT03251378).

(clinicaltrials.gov identifier: NCT04322539).

please visit: www.chi-med.com.

www.lilly.com.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701622/

Study of Elunate® (Fruquintinib) in Chinese Patients With Advanced CRC

https://clinicaltrials.gov/ct2/show/NCT04005066

https://seekingalpha.com/symbol/HCM

https://seekingalpha.com/symbol/LLY

| 28 Jul 2020 Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, July 28, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an amendment to the 2013 License and Collaboration Agreement on Fruquintinib with Lilly Shanghai, an affiliate of Lilly. The 2020 Amendment covers the expansion of Chi-Med’s role in the commercialization of Elunate® (fruquintinib capsules) in China.

Shineco proposes to acquire 73.7% interest in Changzhou Biowin Pharmaceutical

Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration

Shineco proposes to acquire 73.7% interest in Changzhou Biowin Pharmaceutical

Shineco, Inc. Enters into a Letter of Intent to Acquire Controlling Interest in Changzhou Biowin Pharmaceutical Co., Ltd

Published: Jul 27, 2020

BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; Nasdaq: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, as well as various health and well-being-focused plant-based products

about Shineco, please visit http://tianyiluobuma.com.

http://tianyiluobuma.com/

For more information, please visit http://www.czbiowin.com/.

http://www.czbiowin.com/

https://seekingalpha.com/symbol/TYHT

http://www.tianyiluobuma.com/index.php/English/Jishu/index.html

http://www.czbiowin.com/

Shineco, Inc. Enters into a Letter of Intent to Acquire Controlling Interest in Changzhou Biowin Pharmaceutical Co., Ltd Mon July 27, 2020 9:00 AM|GlobeNewswire|About: TYHT BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Shineco, Inc. (TYHT)

Astrazeneca inks $6B oncology deal with Daiichi Sankyo

Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration

Shineco proposes to acquire 73.7% interest in Changzhou Biowin Pharmaceutical

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062

Mon July 27, 2020 2:00 AM|Business Wire|About: AZN, DSNKY

Agreement represents second collaboration between Daiichi Sankyo (DSKYY) and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC)
AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5 billion contingent upon achievement of future regulatory and sales milestones

TOKYO, MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (DSKYF) (hereafter, Daiichi Sankyo)

https://www.businesswire.com/news/home/20200726005033/en/

For more information, please visit: www.DSCancerEnterprise.com.

please visit: www.daiichisankyo.com.

Astrazeneca inks $6B oncology deal with Daiichi Sankyo

Jul. 27, 2020 3:02 AM ET|About: AstraZeneca PLC (AZN)|By: Mamta Mayani, SA News Editor

https://seekingalpha.com/news/3595052-astrazeneca-inks-6b-oncology-deal-daiichi-sankyo

https://seekingalpha.com/symbol/DSKYF

https://www.astrazeneca.com/

AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate PUBLISHED 27 July 2020

Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome

Thu July 23, 2020 7:00 AM|GlobeNewswire|About: OVID

Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome
Ovid and UConn to collaborate on genetic therapy for potential future use alone or in combination with OV101, Ovid’s small molecule therapy for Angelman syndrome in Phase 3 development

NEW YORK and FARMINGTON, Conn., July 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (OVID)(NASDAQ: OVID)

https://ovidrx.com/

https://health.uconn.edu/

https://seekingalpha.com/symbol/OVID

https://investors.ovidrx.com/news-releases/news-release-details/ovid-therapeutics-and-university-connecticut-enter-strategic

Our unique understanding of the complexities of neurologic systems allows us to turn clinical potential into clinical meaning. The Ovid pipeline includes several candidates that would potentially be the first to make a meaningful impact in the lives of individuals with certain rare neurological conditions, and all address significant markets.

Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration

Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Wed July 22, 2020 2:00 AM|GlobeNewswire|About: BVNRY

COPENHAGEN, Denmark, July 22, 2020 – Bavarian Nordic A/S (BVNKF)

For more information visit: www.AdaptVac.com.

For more information visit www.bavarian-nordic.com.

https://www.bavarian-nordic.com/

https://seekingalpha.com/symbol/BVNRY

https://www.adaptvac.com/pipeline

BAVARIAN NORDIC AND ADAPTVAC SIGN FINAL LICENSE AGREEMENT ON COVID-19 VACCINE COPENHAGEN, Denmark, July 22, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the signing of an agreement with AdaptVac, a joint venture established by ExpreS2ion Biotechnologies and NextGen Vaccines spun out of the University of Copenhagen, to license AdaptVac’s proprietary capsid virus like particle (cVLP) technology for coronaviruses, including the COVID-19 indication.

Gilead secures stake in cancer immunotherapy developer Tizona

Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Gilead secures stake in cancer immunotherapy developer Tizona

Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million

Tue July 21, 2020 8:30 AM|Business Wire|About: GILD

– Gilead to Acquire 49.9% Equity Interest in Tizona –

– Gilead Will Have Right to Acquire Remainder of Tizona for up to $1.25 Billion in Potential Option Fees and Future Milestone Payments –

– Gilead Research and Development Funding to Accelerate Tizona’s First-in-Class Pipeline –

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc.

https://www.businesswire.com/news/home/20200721005336/en/

https://www.gilead.com/

https://www.tizonatx.com/

Gilead secures stake in cancer immunotherapy developer Tizona

Jul. 21, 2020 8:42 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3593056-gilead-secures-stake-in-cancer-immunotherapy-developer-tizona

Tizona Therapeutics.

Pipeline Overview Our oncology pipeline is focused on restoring and bolstering immune responses and includes TTX-030. For information about the TTX-030 Phase I/Ib trial, visit: www.clinicaltrials.gov.

Novocure teams up with Merck in lung cancer study

Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Gilead secures stake in cancer immunotherapy developer Tizona

Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer

Wed July 15, 2020 7:30 AM|Business Wire|About: NVCR

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.)

https://www.novocure.com/

https://seekingalpha.com/symbol/NVCR

https://www.businesswire.com/news/home/20200715005430/en/

https://www.novocure.com/our-pipeline/

https://seekingalpha.com/symbol/MRK

https://www.merck.com/index.html

https://www.novocure.com/novocure-announces-clinical-trial-collaboration-with-msd-to-evaluate-tumor-treating-fields-together-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer/

The science of Tumor Treating Fields has the potential to extend beyond glioblastoma. Tumor Treating Fields has shown a consistent anti-mitotic effect in our preclinical and clinical research over the last 19 years.

BiotechVortex™

Medtronic to Acquire Medicrea

MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development

IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine

Medtronic to Acquire Medicrea

Wed July 15, 2020 2:30 AM|Business Wire|About: MDT, MRNTF, MRNTY

Medtronic will become the first company to offer an integrated solution including artificial intelligence-driven surgical planning, personalized spinal implants and robotic assisted surgery

DUBLIN & LYON, France--(BUSINESS WIRE)-- Medtronic plc (MDT), a global leader in medical technology, and Medicrea (MRNTF) (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market – MRNTF)

https://seekingalpha.com/symbol/MRNTY

https://seekingalpha.com/symbol/MRNTF

Medicrea’s product portfolio includes MEDICREA® UNiD® ASI (Adaptive Spine Intelligence) designed to support surgeon workflow in pre-operative planning and create personalized implant solutions for surgery.

https://www.medtronic.com/uk-en/index.html

https://seekingalpha.com/symbol/MDT

https://www.medicrea.com/usa/

https://www.businesswire.com/news/home/20200714006115/en/

https://seekingalpha.com/symbol/MDT

PASS® range The PASS® range by MEDICREA is a highly versatile, low-profile PolyAxial Spine System. Its unique concept allows connection to the rod from a distance, which minimizes stress and provides a strong platform for correction and fusion in all designated indications.

IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine

MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development

IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine

Tue July 14, 2020 8:00 AM|Business Wire|About: IQV

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (IQV) has announced its collaboration with AstraZeneca (LON: AZN) to accelerate development of a potential new vaccine for COVID-19. This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project.

https://www.iqvia.com/

https://www.businesswire.com/news/home/20200714005159/en/

https://seekingalpha.com/symbol/IQV

A time for action: fighting COVID-19 Last updated July 10, 2020

MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development

Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development

Tue July 14, 2020 7:00 AM|PR Newswire|About: SNYPR Newswire

CAMBRIDGE, Mass. and HOUSTON, July 14, 2020 /PRNewswire/ -- Sanofi and The University of Texas MD Anderson Cancer Center

https://www.mdanderson.org/

https://www.prnewswire.com/news-releases/sanofi-and-md-anderson-announce-strategic-collaboration-to-accelerate-oncology-research-and-development-301092433.html

MD Anderson and Sanofi announce strategic collaboration to accelerate oncology research and development New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines MD Anderson News Release July 14, 2020 The University of Texas MD Anderson Cancer Center and Sanofi

Amgen Announces Additional Investment In BeiGene

Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19

MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development

Amgen Announces Additional Investment In BeiGene

Sun July 12, 2020 10:01 PM|PR Newswire|About: AMGN

THOUSAND OAKS, Calif., July 12, 2020 /PRNewswire/ -- Amgen (AMGN)

https://www.amgen.com/

https://www.prnewswire.com/news-releases/amgen-announces-additional-investment-in-beigene-301091975.html

https://www.beigene.com/

https://www.beigene.com/science-and-product-portfolio/pipeline

https://seekingalpha.com/symbol/AMGN

https://seekingalpha.com/symbol/BGNE

Amgen Announces Additional Investment In BeiGene THOUSAND OAKS, Calif., July 12, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN

Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19

Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III

Thu June 11, 2020 9:00 AM|Business Wire|About: SVA

BEIJING & SAO PAULO--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (SVA), (“Sinovac” or the “Company”) (NASDAQ: SVA)

http://www.butantan.gov.br/

http://www.sinovac.com/

https://www.businesswire.com/news/home/20200611005491/en/

https://seekingalpha.com/symbol/SVA

https://seekingalpha.com/news/3582301-sinovac-inks-deal-to-advance-covidminus-19-vaccine

Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III Date: 2020-06-11 Pageview: 9803 BEIJING & SAO PAULO--Sinovac Biotech Ltd., (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, and Instituto Butantan,

Lilly teams up with Evox Therapeutics in neurological disorders

Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19

Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly

Tue June 9, 2020 7:00 AM|PR NewswirePR Newswire

OXFORD, England, June 9, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox's proprietary DeliverEX™ platform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders

https://www.prnewswire.com/news-releases/evox-therapeutics-announces-a-multi-target-rnai-and-antisense-research-collaboration-and-license-agreement-with-lilly-301072380.html

Lilly teams up with Evox Therapeutics in neurological disorders

Jun. 9, 2020 8:36 AM ET|About: Eli Lilly and Company (LLY)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3581471-lilly-teams-up-evox-therapeutics-in-neurological-disorders

https://www.evoxtherapeutics.com/

https://www.evoxtherapeutics.com/Pipeline

PIPELINE Utilising the DeliverEXTM platform, Evox is developing a proprietary pipeline of exosome-based therapeutics for treating life-threatening rare diseases. These therapeutics will have a transformative impact on the lives of patients suffering from rare diseases where there are currently few, if any, treatment options.

UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer

Bristol Myers teams up with UbiVac in study of triplet therapy for breast cancer

Jun. 9, 2020 12:08 PM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor

UbiVac is a clinical stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer.

https://www.ubivac.com/

https://www.ubivac.com/technologies

https://www.ubivac.com/press-releases/2020/6/9/ubivac-announces-clinical-trial-collaboration-with-bristol-myers-squibb-on-combination-immunotherapy-for-advanced-triple-negative-breast-cancer

Technologies

AbbVie and Genmab Announce Broad Oncology Collaboration

UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer

AbbVie and Genmab Announce Broad Oncology Collaboration

Wed June 10, 2020 6:00 AM|PR Newswire|About: ABBV, GMAB

- Companies establish a discovery research collaboration to create additional differentiated antibody therapeutics for cancer

- AbbVie to pay Genmab an upfront payment of USD 750 million with total potential milestone payments of up to USD 3.15 billion

PR Newswire

NORTH CHICAGO, Illinois and COPENHAGEN, Denmark, June 10, 2020 /PRNewswire/ -- AbbVie (ABBV) and Genmab A/S (GNMSF) (Nasdaq: GMAB)

https://www.genmab.com/

https://seekingalpha.com/symbol/GMAB

https://www.genmab.com/product-pipeline

https://www.abbvie.com/

https://news.abbvie.com/news/press-releases/abbvie-and-genmab-announce-broad-oncology-collaboration.htm

https://www.prnewswire.com/news-releases/abbvie-and-genmab-announce-broad-oncology-collaboration-301073533.html

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® and DARZALEX FASPRO™ are trademarks of Janssen Pharmaceutica NV. TEPEZZA™ is a trademark of Horizon Therapeutics plc.

https://seekingalpha.com/symbol/ABBV

Product pipeline Genmab has three approved products in collaboration, DARZALEX® (daratumumab), Arzerra® (ofatumumab) and TEPEZZA™ (teprotumumab-trbw), and is developing a clinical pipeline of antibody therapeutics for the treatment of cancer.

Sequencing by Expansion (SBX™)

UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer

Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration

Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use

Genomics insights generated through sequencing an individual's DNA play a critical role in personalised healthcare and clinical diagnostics of the future
Roche is committed to developing a nanopore sequencer with the aim of providing the healthcare community and ultimately patients with faster and more accurate medical information to predict risk and detect disease
This investment complements the development of Roche’s nanopore technology with the goal of an end-to-end sequencing solution starting from a patient sample to a diagnostic result

Basel, 22 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY)

Roche acquires nanopore sequencing developer Stratos Genomics

May 22, 2020 8:17 AM ET|About: Roche Holding Ltd ADR (RHHBY)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3577123-roche-acquires-nanopore-sequencing-developer-stratos-genomics

https://www.stratosgenomics.com/

Sequencing by Expansion (SBX™) Stratos Genomics is Delivering on the Promise of Nanopore Sequencing

Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

Mon May 11, 2020 7:00 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and AURORA, Colo., May 11, 2020 /PRNewswire/ --

Regeneron Genetics Center will sequence 450,000 informed and consented patients

https://www.cuanschutz.edu/

https://www.regeneron.com/

https://www.prnewswire.com/news-releases/regeneron-and-colorado-center-for-personalized-medicine-announce-major-new-human-genetics-research-collaboration-301056116.html

https://www.cu.edu/

https://medschool.cuanschutz.edu/ccpm

https://seekingalpha.com/symbol/REGN

May 11, 2020 at 7:00 AM EDT Back REGENERON AND COLORADO CENTER FOR PERSONALIZED MEDICINE ANNOUNCE MAJOR NEW HUMAN GENETICS RESEARCH COLLABORATION TARRYTOWN, N.Y. and AURORA, Colo., May 11, 2020 /PRNewswire/ -- Regeneron Genetics Center will sequence 450,000 informed and consented patients Sequencing data will be paired with de-identified health records to aid in genomic medicine, drug discovery and personalized medicine approaches Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Colorado Center for Personalized Medicine (CCPM)

novel HSV-2 vaccine

Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

Genocea Announces Material Transfer and License Option Agreement with Shionogi for Proprietary GEN-003 HSV-2 Antigens

Tue May 19, 2020 7:30 AM|GlobeNewswire|About: GNCA

CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA) (NASDAQ: GNCA)

https://www.genocea.com/

http://www.shionogi.co.jp/en/

https://www.shionogi.com/us/en/

https://seekingalpha.com/symbol/SGIOY

https://seekingalpha.com/symbol/GNCA

GENOCEA ANNOUNCES MATERIAL TRANSFER AND LICENSE OPTION AGREEMENT WITH SHIONOGI FOR PROPRIETARY GEN-003 HSV-2 ANTIGENS May 19, 2020 at 7:30 AM EDT CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced it has entered into a material transfer agreement (MTA) and exclusive license option with Shionogi & Co., Ltd. to develop a novel HSV-2 vaccine using Genocea’s proprietary HSV-2 antigens from the GEN-003 program, which the company discontinued in 2017.

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

Tue May 19, 2020 3:05 AM|PR Newswire|About: RHHBY

Vividion Receives $135 Million Upfront Payment With Potential for Multi-Billion Dollar Future Payments

PR Newswire

SAN DIEGO, May 19, 2020 /PRNewswire/ -- Vividion Therapeutics, a biotechnology

https://vividion.com/

https://www.prnewswire.com/news-releases/vividion-therapeutics-announces-drug-discovery-collaboration-with-roche-focused-on-novel-e3-ligases-301061339.html

https://vividion.com/wp-content/uploads/2020/05/Roche-Vividion-Press-Release_vFINAL.pdf

The Small Molecule Company of the Future

BiotechVortex™

Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted

Roche teams up with Arrakis Therapeutics in RNA-targeted small molecules

Apr. 8, 2020 12:01 PM ET|About: Roche Holding Ltd ADR (RHHBY)|By: Douglas W. House, SA News Editor

https://www.businesswire.com/news/home/20200408005184/en/Arrakis-Therapeutics-Enters-Strategic-Collaboration-License-Agreement

https://arrakistx.com/

https://arrakistx.com/pipeline/

https://arrakistx.com/news/press-releases/arrakis-therapeutics-enters-strategic-collaboration-and-license-agreement-with-roche/

Our Pipeline of rSM Medicines We have taken a multi-pronged approach to building our pipeline of RNA-targeted small molecule (rSM) medicines by pursuing deeply researched, valuable protein drug targets, including:

Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine

Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted

Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development

Thu April 9, 2020 7:50 AM|Business Wire|About: BNTX, PFE

Pfizer (PFE) and BioNTech (BNTX) to jointly develop COVID-19 vaccine, initially in the United States and Europe, and scale-up manufacturing capacity to support global supply
Potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval by regulatory authorities, and then rapidly scale up capacity to produce hundreds of millions of doses in 2021.
BioNTech will contribute multiple mRNA vaccine candidates as part of its BNT162 COVID-19 vaccine program, which are expected to enter human testing in April 2020
Pfizer will contribute its leading global vaccine clinical research and development, regulatory, manufacturing and distribution infrastructure and capabilities
BioNTech will receive an upfront payment of $185 million, including an equity investment of approximately $113 million, and be eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million

MAINZ, Germany & NEW YORK--(BUSINESS WIRE)-- BioNTech SE, and Pfizer Inc.

https://www.businesswire.com/news/home/20200409005405/en/

https://www.pfizer.com/

https://seekingalpha.com/news/3559589-pfizer-identifies-lead-covidminus-19-candidate

https://biontech.de/

https://seekingalpha.com/symbol/BNTX

https://www.wsj.com/articles/pfizer-identifies-lead-coronavirus-drug-candidate-11586427303?mod=pls_whats_news_us_business_f

Pfizer Identifies Lead Coronavirus Drug Candidate

Experimental medicine to be tested on patients this summer; arthritis therapy Xeljanz considered, too

By Jared S. Hopkins

JAREDSHOPKINS

Updated April 9, 2020 3:56 pm ET

PFIZER AND BIONTECH ANNOUNCE FURTHER DETAILS ON COLLABORATION TO ACCELERATE GLOBAL COVID-19 VACCINE DEVELOPMENT

NeoImmuneTech Collaboration w/ BMY to Evaluate NT-I7 (Hyleukin-7™) in Combination with Nivolumab

Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted

NeoImmuneTech Collaboration w/ BMY to Evaluate NT-I7 (Hyleukin-7™) in Combination with Nivolumab

NeoImmuneTech Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate NT-I7 (Hyleukin-7™) in Combination with Nivolumab

Thu April 9, 2020 7:00 AM|Business Wire|About: BMY

ROCKVILLE, Md.--(BUSINESS WIRE)-- NeoImmuneTech, Inc.,

https://www.businesswire.com/news/home/20200409005106/en/

http://neoimmunetech.com/

NIT is currently conducting multiple clinical trials of NT-I7 (Hyleukin-7TM) as a monotherapy and in combination with leading immunotherapeutics such as checkpoint inhibitors, cancer vaccines, and more. In addition, NIT is relentlessly conducting proof-of-concept animal studies in additional indications to further strengthen our pipeline and broaden the proof of applicability of NT-I7.

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

NeoImmuneTech Collaboration w/ BMY to Evaluate NT-I7 (Hyleukin-7™) in Combination with Nivolumab

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Tue April 14, 2020 7:00 AM|GlobeNewswire|About: SNY

Sanofi (SNY) and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine
Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021

PARIS and LONDON – April 14, 2020 - Sanofi and GSK

https://www.gsk.com/en-gb/

https://seekingalpha.com/symbol/GSK

https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-14-13-00-00

14 April 2020 Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 For media and investors only Issued: London, UK Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second half of 2021

Moderna teams up with Ginkgo Bioworks to improve manufacturing processes

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Moderna teams up with Ginkgo Bioworks to improve manufacturing processes

Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response

Wed April 15, 2020 9:00 AM|PR Newswire|About: MRNAPR Newswire

BOSTON, April 15, 2020 /PRNewswire/ -- Ginkgo Bioworks

https://www.ginkgobioworks.com/

https://www.prnewswire.com/news-releases/ginkgo-bioworks-provides-support-on-process-optimization-to-moderna-for-covid-19-response-301040876.html

https://seekingalpha.com/symbol/MRNA

OUR PLATFORM FoundriesCodebase Read More

Microsoft's newly launched 'plasmabot'

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Moderna teams up with Ginkgo Bioworks to improve manufacturing processes

Meet Microsoft's newly launched 'plasmabot'

Apr. 19, 2020 5:25 AM ET|About: Microsoft Corporation (MSFT)|By: Yoel Minkoff, SA News Editor

Microsoft is launching a ‘plasmabot’ to encourage people who recovered from the virus to donate their plasma as a possible treatment

PUBLISHED SAT, APR 18 20206:31 PM EDT Christina Farr@CHRISSYFARR
https://www.cnbc.com/2020/04/18/microsoft-plasmabot-encourages-covid-19-survivors-to-donate-plasma.html

https://seekingalpha.com/symbol/MSFT

https://www.cnbc.com/quotes/?symbol=MSFT

https://www.history.com/news/blood-plasma-covid-19-measles-spanish-flu

Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies

Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells

Tue April 21, 2020 4:15 PM|Business Wire|About: GILD

-- Collaboration to Leverage oNKo-innate’s Deep Expertise in NK Cell Tumor Biology to Discover Novel Therapies in Immuno-Oncology and Cell Therapy --

FOSTER CITY, Calif. & SANTA MONICA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD), Kite, a Gilead Company, and oNKo-innate

https://www.businesswire.com/news/home/20200421005271/en/

https://www.onko-innate.com/

https://www.kitepharma.com/

https://www.gilead.com/

https://www.onko-innate.com/gilead-kite-collaboration

NK cell biology as a screening tool

https://www.onko-innate.com/gilead-kite-collaboration

Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells

Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration

Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies

Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

Mon April 27, 2020 8:30 AM|Business Wire|About: VRTX

Affinia Therapeutics’ proprietary AAV vector technology to be used in Vertex’s genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis

BOSTON & WALTHAM, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX) and Affinia Therapeutics

https://www.businesswire.com/news/home/20200427005151/en/

https://www.affiniatx.com/

https://www.vrtx.com/

https://investors.vrtx.com/news-releases/news-release-details/vertex-pharmaceuticals-and-affinia-therapeutics-establish-multi

https://seekingalpha.com/symbol/VRTX

Research and Pipeline Vertex is focused on discovering, developing and commercializing innovative medicines so people with serious diseases can lead better lives. Our scientists don’t see the impossible as an obstacle; they see it as a good place to start.

AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine

Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies

WuXi Biologics & Aravive Collaboration to Develop High-Affinity Bispecific Antibodies Target Cancer

AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine

PUBLISHED30 April 2020

Collaboration will enable global development,
manufacturing and distribution of the vaccine.

AstraZeneca teams up Oxford U. on COVID-19 vaccine

Apr. 30, 2020 6:38 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3566711-astrazeneca-teams-up-oxford-u-on-covidminus-19-vaccine

AstraZeneca to Make Oxford Vaccine as Covid Race Heats Up The drug company will make and distribute the potential coronavirus vaccine.

WuXi Biologics & Aravive Collaboration to Develop High-Affinity Bispecific Antibodies Target Cancer

WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform

Thu April 30, 2020 7:00 AM|PR Newswire|About: ARAV, WXXWY

SHANGHAI and HOUSTON, April 30, 2020 /PRNewswire/ -- WuXi Biologics (WXXWY) ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Aravive, Inc. (ARAV)

https://seekingalpha.com/symbol/ARAV

https://seekingalpha.com/symbol/WXXWY

https://aravive.com/

https://www.wuxibiologics.com/

https://www.prnewswire.com/news-releases/wuxi-biologics-and-aravive-form-strategic-collaboration-to-develop-novel-high-affinity-bispecific-antibodies-targeting-cancer-and-fibrosis-using-the-wuxibody-platform-301050119.html

https://ir.aravive.com/news-releases/news-release-details/aravive-and-wuxi-biologics-form-strategic-collaboration-develop

Pipeline Our lead product candidate, AVB-500, is an ultra-high affinity decoy protein that starves the GAS6/AXL signaling pathway.

BioMarin Gene Therapy w/DiNAQOR in Collaboration & License Agreement= Rare Genetic Cardiomyopathies

WuXi Biologics & Aravive Collaboration to Develop High-Affinity Bispecific Antibodies Target Cancer

BioMarin Gene Therapy w/DiNAQOR in Collaboration & License Agreement= Rare Genetic Cardiomyopathies

BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies

Sun May 3, 2020 4:01 PM|PR Newswire|About: BMRN

SAN RAFAEL, Calif., May 3, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR),

https://www.biomarin.com/

http://dinaqor.com/

https://www.prnewswire.com/news-releases/biomarin-extends-gene-therapy-leadership-with-dinaqor-in-a-preclinical-collaboration-and-license-agreement-to-develop-gene-therapies-for-rare-genetic-cardiomyopathies-301051582.html

https://seekingalpha.com/symbol/BMRN

BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies SAN RAFAEL, Calif., May 3, 2020 — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR)

Lilly & Junshi Biosciences to Co-develop Antibody Therapies for Prevention & Treatment of COVID-19

WuXi Biologics & Aravive Collaboration to Develop High-Affinity Bispecific Antibodies Target Cancer

BioMarin Gene Therapy w/DiNAQOR in Collaboration & License Agreement= Rare Genetic Cardiomyopathies

Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19

Mon May 4, 2020 8:00 AM|PR Newswire|About: LLY

SHANGHAI and INDIANAPOLIS, May 4, 2020 /PRNewswire/ -- Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (LLY)

http://junshipharma.com/en/Index.html

http://junshipharma.com/en/Treatment.html

https://investor.lilly.com/news-releases/news-release-details/lilly-and-junshi-biosciences-co-develop-antibody-therapies

https://www.prnewswire.com/news-releases/lilly-and-junshi-biosciences-to-co-develop-antibody-therapies-for-the-prevention-and-treatment-of-covid-19-301051788.html

https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0504/2020050400017.pdf

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 (a joint stock company incorporated in the People’s Republic of China with limited liability) (Stock code: 1877) INSIDE INFORMATION－ ENTERING INTO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH LILLY

http://www.caixin.com/2020-05-05/101550272.html

Eli Lilly teams up with Chinese company Junshi to develop Covid-19 therapy

https://www.caixinglobal.com/2020-05-05/china-business-digest-global-infections-top-358-million-kingsoft-cloud-super-sizes-fundraising-target-for-us-ipo-101550249.html

THERAPEUTIC AREAS

BiotechVortex™

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline

Thu April 2, 2020 8:00 AM|Business Wire|About: HZNP

-- Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment --

-- Compelling Fit with Horizon’s Strategy to Acquire and Develop Medicines Targeting Diseases with High Unmet Need with Focus on Its Core Therapeutic Areas --

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP)

https://www.horizontherapeutics.com/

https://www.horizontherapeutics.com/our-pipeline/

https://www.businesswire.com/news/home/20200402005203/en/

https://seekingalpha.com/symbol/HZNP

Horizon snaps up Curzion Pharma and its ex-Sanofi rare disease drug by Ben Adams | Apr 3, 2020 8:25am

Becton Dickinson, BioGX Get FDA Emergency Use Authorization For Rapid SARS-CoV-2 Test

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

BD, BioGX Announce FDA Emergency Use Authorization for New COVID-19 Diagnostic for Use in U.S.

Fri April 3, 2020 6:59 AM|PR Newswire|About: BDXPR Newswire

FRANKLIN LAKES, N.J. and BIRMINGHAM, Ala., April 3, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX), a leading global medical technology company, and BioGX Inc.

https://www.bd.com/en-us

http://biogx.com/

https://www.prnewswire.com/news-releases/bd-biogx-announce-fda-emergency-use-authorization-for-new-covid-19-diagnostic-for-use-in-us-301034652.html

https://seekingalpha.com/symbol/BDX

http://biogx.com/news/becton-dickinson-biogx-get-fda-emergency-use-authorization-for-rapid-sars-cov-2-test

https://biogx.com/

PRODUCTS

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product

Gilead Sciences & Second Genome Collaboration in Biomarker & Inflammatory Bowel Disease Drug

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Mon April 6, 2020 8:01 AM|GlobeNewswire|About: GSK, VIR

Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks
Promising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five months
GSK to make equity investment of $250 million in Vir

LONDON and SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (GSK) and Vir Biotechnology, Inc. (VIR)

https://www.vir.bio/science/#programs

https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus

https://seekingalpha.com/symbol/GSK

Technology platforms Our four current technologies are designed to stimulate and enhance the immune system.

Gilead Sciences & Second Genome Collaboration in Biomarker & Inflammatory Bowel Disease Drug

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

Gilead Sciences & Second Genome Collaboration in Biomarker & Inflammatory Bowel Disease Drug

Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

Mon April 6, 2020 6:15 AM|Business Wire|About: GILD

-- Multi-year, Multi-program Agreement Leverages Latest Insights of Microbiome --

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Second Genome

https://www.businesswire.com/news/home/20200406005220/en/

https://www.secondgenome.com/

https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-sciences-and-second-genome-announce-strategic-collaboration-in-biomarker-and-inflammatory-bowel-disease-drug-discovery

Second Genome has developed a rich pipeline of drug candidates through our differentiated approach.

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs

Mon April 6, 2020 7:00 AM|Business Wire|About: ALNY, DRNA

- Dicerna to Lead Global Clinical Development and U.S. Commercialization of its DCR-A1AT and Alnylam’s ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease; Alnylam Retains Post-Phase 3 Opt-in Right for Ex-U.S. Commercialization -

- Companies Complete Non-Exclusive Intellectual Property Cross-License Agreement for the Development and Commercialization of Alnylam’s Lumasiran and Dicerna’s Nedosiran Investigational Programs for Primary Hyperoxaluria -

CAMBRIDGE, Mass. & LEXINGTON, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (ALNY) (Nasdaq: ALNY), and Dicerna Pharmaceuticals, Inc. (DRNA) (Nasdaq: DRNA)

https://www.alnylam.com/

https://www.alnylam.com/alnylam-rnai-pipeline/

https://seekingalpha.com/symbol/ALNY

https://dicerna.com/

https://dicerna.com/pipeline/

https://seekingalpha.com/symbol/DRNA

https://www.businesswire.com/news/home/20200406005200/en/

Alpha-1 antitrypsin deficiency

https://ghr.nlm.nih.gov/condition/alpha-1-antitrypsin-deficiency#

Primary hyperoxaluria

https://ghr.nlm.nih.gov/condition/primary-hyperoxaluria

RNAi therapies to target the cause of disease

Regeneron & Zai Lab Announce Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

Alnylam & Dicerna RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Liver Disease

Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

Wed April 8, 2020 6:00 AM|GlobeNewswire|About: REGN, ZLAB

Zai Lab (ZLAB) obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau

Collaboration will also support enrollment of regional patients into Regeneron’s global trials evaluating REGN1979 in B-cell non-Hodgkin lymphoma (B-NHL)

Zai Lab to host conference call and webcast today at 8:00 a.m. EST

TARRYTOWN, N.Y. and SHANGHAI, China, April 08, 2020 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Zai Lab Limited

https://www.regeneron.com/

http://www.zailaboratory.com/

https://www.regeneron.com/pipeline

http://www.zailaboratory.com/pipeline/list.aspx

https://seekingalpha.com/symbol/ZLAB

https://seekingalpha.com/symbol/REGN

INTERACT WITH THE REGENERON PIPELINE Pipeline last updated: February 13, 2020

BiotechVortex™

Generation Bio & Vir Biotechnology Collaborate on Scalable Non-Viral Gene Therapy Platform

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19

Mon March 30, 2020 7:00 AM|Business Wire|About: VIRQ4: 03-26-20 Earnings SummaryEPS of $-0.69 misses by $-0.06 Revenue of $0.98M (-% Y/Y) misses by $-1.59M

CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Generation Bio and Vir Biotechnology (VIR) (Nasdaq: VIR)

https://www.businesswire.com/news/home/20200330005148/en/

https://generationbio.com/

https://www.vir.bio/pipeline/

We are committed to enabling generations of people with genetic diseases to live long, full lives.

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines

Tue March 31, 2020 6:30 AM|PR Newswire|About: LLY

INDIANAPOLIS and OXFORD, England, March 31, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced an exclusive global licensing and research collaboration with Sitryx,

https://www.prnewswire.com/news-releases/lilly-and-sitryx-announce-licensing-and-research-collaboration-to-discover-and-develop-new-immunometabolic-medicines-301032137.html

http://www.sitryx.com/

http://www.sitryx.com/news-and-events/press-releases/2020/

Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease modifying therapeutics in immuno-oncology and immuno-inflammation.

NanoViricides, Inc. Progress on COVID-19 Drug Encouraging

Lilly & Sitryx Announce Research Collaboration to Discover & Develop New Immunometabolic Medicines

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

NanoViricides, Inc. Progress on COVID-19 Drug Encouraging

Tue March 31, 2020 7:30 AM|Newsfile|About: NNVCNewsfile Corp

The Company's Update on its Development of COVID-19 Drug Candidate is Promising

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2020) - NanoViricides, Inc. (NNVC) (

http://www.nanoviricides.com/

http://www.nanoviricides.com/pipeline.html

https://smallcapsdaily.com/nanoviricides-the-latest-covid-19-drug-update-looks-promising/

https://seekingalpha.com/symbol/NNVC

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES

Tue March 31, 2020 2:00 PM|GlobeNewswire|About: SRNE

SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product candidates.

https://sorrentotherapeutics.com/

https://som.utmb.edu/

Immuno-Oncology

https://sorrentotherapeutics.com/pipeline/

https://seekingalpha.com/symbol/SRNE

COVID-19: UPDATE FROM THE SCHOOL OF MEDICINE

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

Tue March 31, 2020 4:05 PM|PR Newswire|About: RARE, RGNX

- Agreement for use of NAV Vectors expands ongoing relationship between Ultragenyx and REGENXBIO

PR Newswire

ROCKVILLE, Md. and NOVATO, Calif., March 31, 2020 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (RARE),

https://www.ultragenyx.com/

https://www.regenxbio.com/

https://www.ultragenyx.com/pipeline/

https://www.regenxbio.com/therapeutic-programs/

https://seekingalpha.com/symbol/RGNX

https://seekingalpha.com/symbol/RARE

Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

SORRENTO & THE UNIVERSITY OF TEXAS MEDICAL AT GALVESTON ENTER PRECLINICAL TESTING FOR COVID-19

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

Tue March 31, 2020 4:05 PM|GlobeNewswire|About: EBS, NVAX

CDMO agreement for NanoFlu to support pathway to licensure
Expanded collaboration now includes NanoFlu and COVID-19 vaccine candidate

GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (EBS) today announced an agreement with Novavax, Inc. (NVAX)

https://www.emergentbiosolutions.com/

https://novavax.com/

https://www.emergentbiosolutions.com/pipeline

https://novavax.com/page/8/vaccine-technology.html

https://seekingalpha.com/symbol/NVAX

https://seekingalpha.com/symbol/EBS

NanoFlu – Nanoparticle Seasonal Influenza Vaccine - Older Adults (65+ yrs)

https://novavax.com/page/11/clinical-stage-pipeline.html

Product Candidate & Device Candidate

BiotechVortex™

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19

Tue March 24, 2020 9:32 AM|GlobeNewswire|About: SRNE

ACE-MABTM is a proprietary bi-specific fusion protein that binds to the spike protein of coronaviruses, including SARS-CoV-2 and SARS-CoV, which is expected to block SARS-CoV-2 from binding and infecting respiratory epithelial cells or ACE2-expressing cells to interrupt the viral life cycle
ACE-MAB is in the cGMP cell line development stage by our strategic partner, Mabpharm Limited, and could be ready for large-scale production in Mabpharm’s 30,000 m2 cGMP facilities in China for human clinical trials and commercialization upon receipt of requisite regulatory approvals
Sorrento has been granted an exclusive license to develop and commercialize the ACE-MAB product candidate in the North American and European markets

SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE) today announced it has entered into an exclusive license agreement with China-based antibody biopharmaceutical company, Mabpharm Limited (Hong Kong Stock Exchange: 2181HK,

https://sorrentotherapeutics.com/

http://www.mabpharm.cn/en/index.php

https://sorrentotherapeutics.com/pipeline/

https://seekingalpha.com/symbol/SRNE

https://apnews.com/Globe%20Newswire/5a08618b12f6f2f70ac2bc199b48324a

http://www.mabpharm.cn/en/research_product.php

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19 Sorrento Therapeutics, Inc. today

Multi-Lingual Support = Global MediXchange of Combating COVID-19 (GMCC)-Medical Personnel Worldwide

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

Multi-Lingual Support From the Global MediXchange of Combating COVID-19 (GMCC) Programme to Further Enable Sharing Among Medical Personnel Worldwide

Wed March 25, 2020 11:43 PM|Business Wire|About: BABA

HANGZHOU, China--(BUSINESS WIRE)

https://www.alibabacloud.com/solutions/dingtalk/international-medical-expert-communication-platform?spm=a3c0i.14157329.6596852130.2.1bf2772d5A46tB

Resources Sharing Center

Fight COVID-19 without having to start from scratch

https://covid-19.alibabacloud.com/#J_8102420620

The Chinese Telemedicine Team
Is Here to Fight against COVID-19

International Medical Expert Communication Center
Is Officially Launched

https://covid-19.alibabacloud.com/

https://www.businesswire.com/news/home/20200325005799/en/

https://seekingalpha.com/symbol/BABA

International Medical Expert Communication Center Alibaba's DingTalk provides a communication center for experts all over the world to communicate seamlessly with global doctors who can share their invaluable experience of fighting coronavirus disease 2019 (COVID-19).

Dynavax & CEP Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT & COMMERCIALIZATION OF ACE-MAB™ TO TREAT COVID-19

Dynavax & CEP Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

Thu March 26, 2020 7:30 AM|GlobeNewswire|About: DVAXGlobeNewswire

EMERYVILLE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (DVAX) (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI)

https://www.dynavax.com/

https://cepi.net/

https://www.fda.gov/

http://investors.dynavax.com/node/17866/pdf

https://seekingalpha.com/symbol/DVAX

http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-cepi-announce-collaboration-support-global-effort

New vaccines for a safer world The Coalition for Epidemic Preparedness Innovations (CEPI) is a global alliance financing and coordinating the development of vaccines against emerging infectious diseases.

Sanofi & Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Dynavax & CEP Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

Sanofi Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Fri March 27, 2020 2:00 AM|GlobeNewswire|About: SNY, TBIO

The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development

PARIS and LEXINGTON, Mass., March 27, 2020 (GLOBE NEWSWIRE) -- Sanofi Pasteur, the vaccines global business unit of Sanofi (SNY), and Translate Bio (TBIO)

https://translate.bio/

https://seekingalpha.com/symbol/TBIO

https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00

Translate Bio Provides MRT5005 Program Updates

Thu March 26, 2020 4:30 PM|GlobeNewswire|About: TBIO

-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis –

-- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial operations; updated interim data readout timing to be provided at later date --

LEXINGTON, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Translate Bio (TBIO)

https://seekingalpha.com/pr/17820487-translate-bio-provides-mrt5005-program-updates

https://translate.bio/pipeline/

Our MRTTM platform is potentially applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease. Our MRTTM platform may also be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as infectious disease and oncology

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19

Sanofi & Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Medtronic Shares Ventilation Design Specifications to Increase Global Ventilator Production

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Mon March 30, 2020 7:22 AM|PR Newswire|About: JNJ

Johnson & Johnson (JNJ) and BARDA

https://www.janssen.com/infectious-diseases-and-vaccines/patented-technologies

Novel Coronavirus, SARS-CoV-2

https://www.jnj.com/coronavirus

https://www.jnj.com/

https://www.prnewswire.com/news-releases/johnson--johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-us-department-of-health--human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use-301031582.html

https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use

Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses GloballyApr 23, 2020Company Signs Agreement with Emergent BioSolutions in the U.S. As Part of its InvestmentFirst in Series of Anticipated Strategic Collaborations Designed to Further the Company's Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19

NEW BRUNSWICK, N.J., April 23, 2020 /PRNewswire/ -- Johnson & Johnson (the Company) (NYSE: JNJ) today announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, I

https://johnsonandjohnson.gcs-web.com/news-releases/news-release-details/johnson-johnson-announces-collaboration-expand-manufacturing

https://www.emergentbiosolutions.com/manufacturing-expertise

https://www.emergentbiosolutions.com/

Cutting-edge technologies are the driving force behind our strong research and development pipeline

Medtronic Shares Ventilation Design Specifications to Increase Global Ventilator Production

Sanofi & Translate Bio to Collaborate to Develop a Novel mRNA Vaccine Candidate Against COVID-19

Medtronic Shares Ventilation Design Specifications to Increase Global Ventilator Production

Medtronic Shares Ventilation Design Specifications to Accelerate Efforts to Increase Global Ventilator Production

Mon March 30, 2020 8:15 AM|GlobeNewswire|About: MDT

DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (MDT) (NYSE:MDT)

https://www.fda.gov/media/136318/download

https://www.medtronic.com/us-en/index.html

http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-shares-ventilation-design-specifications-accelerate

https://seekingalpha.com/symbol/MDT

Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency Guidance for Industry and Food and Drug Administration Staff March 2020

BiotechVortex™

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development

Fri March 13, 2020 9:41 AM|PR Newswire|About: JNJPR Newswire

NEW BRUNSWICK, N.J., March 13, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC)

Cutting-edge technologies are the driving force behind our strong research and development pipeline

https://www.janssen.com/infectious-diseases-and-vaccines/patented-technologies

https://www.jnj.com/johnson-johnson-announces-collaboration-with-u-s-department-of-health-human-services-to-accelerate-development-of-a-potential-novel-coronavirus-vaccine

Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine

Janssen joins forces with Biomedical Advanced Research and Development Authority (BARDA) to protect communities against threat of a global COVID-19 pandemic

https://www.jnj.com/coronavirus

https://www.jnj.com/johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat

AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals

Mon March 16, 2020 7:30 AM|PR Newswire|About: ACRX

Tetraphase shareholders to receive 14.6% of AcelRx fully diluted shares outstanding in the transaction

Transaction broadens AcelRx's portfolio and enhances its commercial presence and strategy to become a leader in providing innovative treatments to healthcare institutions

AcelRx and Tetraphase also enter into co-promotion agreement expected to generate significant commercial synergies immediately

Acquisition expected to close in Q2 2020

PR Newswire

REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX)

https://www.acelrx.com/

https://www.tphase.com/#

https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-acquire-tetraphase-pharmaceuticals-301024578.html

https://www.tphase.com/products/xerava/

https://seekingalpha.com/symbol/ACRX

AcelRx to acquire Tetraphase in a stock for stock transaction Tetraphase shareholders to receive 14.6% of AcelRx fully diluted shares outstanding in the transaction Transaction broadens AcelRx's portfolio and enhances its commercial presence and strategy to become a leader in providing innovative treatments to healthcare institutions AcelRx and Tetraphase also enter into co-promotion agreement expected to generate significant commercial synergies immediately Acquisition expected to close in Q2 2020 REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

IDE196, a Protein Kinase C (PKC) inhibitor, and binimetinib, a MEK inhibitor

J & J Collaboration with Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine

Danaher Acquisition of the Biopharma Business of General Electric Life Sciences

IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations

Wed March 18, 2020 6:00 AM|PR Newswire|About: IDYA, PFEPR Newswire

SOUTH SAN FRANCISCO, Calif., March 18, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (IDYA),

https://www.prnewswire.com/news-releases/ideaya-and-pfizer-enter-clinical-trial-collaboration-and-supply-agreement-to-evaluate-clinical-combination-of-ide196-and-binimetinib-in-solid-tumors-harboring-gnaq-or-gna11-hotspot-mutations-301025907.html

https://www.ideayabio.com/

https://seekingalpha.com/symbol/IDYA

https://clinicaltrials.gov/ct2/show/NCT03947385?term=ideaya&draw=2&rank=1

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Breakthrough Oncology Medicines

Danaher Acquisition of the Biopharma Business of General Electric Life Sciences

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Danaher Acquisition of the Biopharma Business of General Electric Life Sciences

Danaher Receives Clearance From U.S. Federal Trade Commission For The Acquisition Of The Biopharma Business Of General Electric Life Sciences

Thu March 19, 2020 6:50 PM|PR Newswire|About: DHR, GE

WASHINGTON, March 19, 2020 /PRNewswire/ -- Danaher Corporation (DHR)

https://www.danaher.com/

https://www.prnewswire.com/news-releases/danaher-receives-clearance-from-us-federal-trade-commission-for-the-acquisition-of-the-biopharma-business-of-general-electric-life-sciences-301027237.html

https://seekingalpha.com/symbol/DHR

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Mon March 23, 2020 7:00 AM|GlobeNewswire|About: ACIU

CHF 10 million milestone recognizes development progress
Updated financial terms add a new CHF 60 million milestone for Phase 2 initiation
Total potential deal value is now CHF 1.86 billion, up from CHF 1.82 billion

LAUSANNE, Switzerland, March 23, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU) (NASDAQ: ACIU)

https://www.acimmune.com/

https://ir.acimmune.com/news-releases/news-release-details/ac-immune-and-lilly-announce-license-and-collaboration-agreement?field_nir_news_date_value%5bmin%5d=2019

https://ir.acimmune.com/news-releases/news-release-details/ac-immune-initiates-phase-1-study-aci-3024-small-molecule-tau?field_nir_news_date_value%5bmin%5d=2019

https://seekingalpha.com/symbol/ACIU

AC Immune and Lilly Announce License and Collaboration Agreement December 12, 2018

Updates from Lilly about insulin supply and affordability

AC Immune Receives Second and Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership

Updates from Lilly about insulin supply and affordability

Tue March 24, 2020 8:00 AM|PR Newswire|About: LLY

INDIANAPOLIS, March 24, 2020 /PRNewswire/

https://www.prnewswire.com/news-releases/updates-from-lilly-about-insulin-supply-and-affordability-301028654.html

IDF DIABETES ATLAS

9th edition 2019

https://diabetesatlas.org/en/

https://www.facebook.com/LillyDiabetesUS/

https://www.lillydiabetes.com/

Updates from Lilly about insulin supply and affordability 03/24/2020 Download PDF INDIANAPOLIS, March 24, 2020 /PRNewswire/

BiotechVortex™

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses

Wed March 11, 2020 8:00 AM|GlobeNewswire|About: VIRGlobeNewswire

SAN FRANCISCO, March 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology (VIR), Inc. (Nasdaq: VIR)

https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-research-collaboration-national

Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses 03/11/20 at 8:00 AM EDT PDF Version Joint research project to include SARS-CoV-2 SAN FRANCISCO, March 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR)

Vir Biotechnology to Collaborate w Biogen on Manufacturing of Antibodies to Treat COVID-19

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19

03/12/20 at 8:00 AM EDTPDF Version

SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has signed a letter of intent with Biogen Inc. (Nasdaq: BIIB)

Vir Biotech up 27% premarket on COVID-19 deal with Biogen

Mar. 12, 2020 8:40 AM ET|About: Vir Biotechnology, Inc. (VIR)|By: Douglas W. House, SA News Editor

https://seekingalpha.com/news/3551009-vir-biotech-up-27-premarket-on-covidminus-19-deal-biogen

Sutro Biopharma Extension of First Cytokine Derivative Research Program Under Collaboration w Merck

Vir Biotechnology Research Collaboration with National Institutes of Health Vaccine Research Center

Sutro Biopharma Extension of First Cytokine Derivative Research Program Under Collaboration w Merck

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

Thu March 12, 2020 7:00 AM|PR Newswire|About: STRO

SOUTH SAN FRANCISCO, Calif., March 12, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO)

https://www.sutrobio.com/

https://www.prnewswire.com/news-releases/sutro-biopharma-announces-extension-of-first-cytokine-derivative-research-program-under-collaboration-with-merck-301022013.html

https://seekingalpha.com/symbol/STRO

https://seekingalpha.com/symbol/MRK

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck March 12, 2020 SOUTH SAN FRANCISCO, Calif., March. 12, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Merck,

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

Sutro Biopharma Extension of First Cytokine Derivative Research Program Under Collaboration w Merck

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

Thu March 12, 2020 7:00 AM|PR Newswire

CARLSBAD, Calif., March 12, 2020 /PRNewswire/ -- Thermo Fisher Scientific

https://www.thermofisher.com/us/en/home.html

http://thermofisher.mediaroom.com/2020-03-12-Thermo-Fisher-Scientific-Signs-Agreement-with-Janssen-to-Co-Develop-Companion-Diagnostic-for-Cancer

https://www.prnewswire.com/news-releases/thermo-fisher-scientific-signs-agreement-with-janssen-to-co-develop-companion-diagnostic-for-cancer-301022011.html

https://seekingalpha.com/symbol/TMO

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer CARLSBAD, Calif., March 12, 2020 /PRNewswire/ -- Thermo Fisher Scientific announced today it has signed an agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to co-develop a companion diagnostic (CDx) in oncology. The CDx will support clinical trial enrollment globally.

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

Wed March 11, 2020 10:45 AM|GlobeNewswire|About: NVAX

Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University
Phase 2b clinical efficacy study of experimental malaria vaccine with Matrix‑M nearing completion in Burkina Faso

GAITHERSBURG, Md., March 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX)

https://www.who.int/publications-detail/world-malaria-report-2019

https://www.novavax.com/

https://www.seruminstitute.com/

https://www.novavax.com/page/11/clinical-stage-pipeline.html

https://seekingalpha.com/symbol/NVAX

CLINICAL STAGE PIPELINE

AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19

Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

AbCellera and Lilly to Co-develop Antibody Therapies for the Treatment of COVID-19

Thu March 12, 2020 6:11 PM|PR Newswire|About: LLYPR Newswire

VANCOUVER, British Columbia and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (LLY)

https://www.abcellera.com/

https://www.abcellera.com/news/2020-03-abcellera-and-lilly-codevelopment

https://www.prnewswire.com/news-releases/abcellera-and-lilly-to-co-develop-antibody-therapies-for-the-treatment-of-covid-19-301022689.html

https://investor.lilly.com/news-releases/news-release-details/abcellera-and-lilly-co-develop-antibody-therapies-treatment

ABCELLERA AND LILLY TO CO-DEVELOP ANTIBODY THERAPIES FOR THE TREATMENT OF COVID-19

BiotechVortex™

CVS Kidney Care, Satellite Healthcare Strategic Relationship to Care of Patients w/ Kidney Disease

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

CVS Kidney Care, Satellite Healthcare Strategic Relationship to Care of Patients w/ Kidney Disease

CVS Kidney Care, Satellite Healthcare Enter Strategic Relationship to Advance the Care of Patients with Kidney Disease

Mon March 2, 2020 4:30 PM|PR Newswire|About: CVS

WOONSOCKET, R.I. and SAN JOSE, Calif., March 2, 2020 /PRNewswire/ -- CVS Kidney Care, a CVS Health (CVS) company, and Satellite Healthcare

https://www.cvshealth.com/

https://www.satellitehealth.com/

https://www.prnewswire.com/news-releases/cvs-kidney-care-satellite-healthcare-enter-strategic-relationship-to-advance-the-care-of-patients-with-kidney-disease-301014761.html

https://seekingalpha.com/symbol/CVS

Satellite Healthcare is one of the nation's leading not-for-profit providers of kidney dialysis and related services.

Thermo Fisher Scientific to Acquire QIAGEN N.V.

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

CVS Kidney Care, Satellite Healthcare Strategic Relationship to Care of Patients w/ Kidney Disease

Thermo Fisher Scientific to Acquire QIAGEN N.V.

Tue March 3, 2020 2:53 AM|PR Newswire|About: QGEN, TMO

- Complements leading life sciences offering with innovative sample preparation, assay and bioinformatics technologies

- Creates significant value and is expected to be immediately accretive to adjusted earnings per share after close

PR Newswire

WALTHAM, Mass. and VENLO, Netherlands, March 3, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (TMO), the world leader in serving science, and QIAGEN N.V. (QGEN)

https://www.thermofisher.com/us/en/home.html

https://www.qiagen.com/us/

https://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-acquire-qiagen-nv-301015072.html

https://seekingalpha.com/symbol/QGEN

https://seekingalpha.com/symbol/TMO

http://thermofisher.mediaroom.com/2020-03-03-Thermo-Fisher-Scientific-to-Acquire-QIAGEN-N-V,1

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

EC signs off on Allergan sale of brazikumab

Mar. 3, 2020 9:09 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor

https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-recover-the-global-rights-to-brazikumab-medi2070-from-allergan-27012020.html

AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan PUBLISHED 27 January 2020

Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

The European Commission (EC) has approved Allergan's divestment of IL-23 inhibitor brazikumab to AZN

Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology

Tue March 3, 2020 5:30 PM|Business Wire|About: BMY

NEW YORK & PARIS--(BUSINESS WIRE)-- Regulatory News:

Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, and Bristol-Myers Squibb Company (BMY)

http://www.voluntis.com/

https://www.businesswire.com/news/home/20200303006062/en/

https://news.bms.com/press-release/httpwwwvoluntiscomennewsnews-12020voluntis-and-bristol-myers-squibb-co-develop-digital

VOLUNTIS AND BRISTOL-MYERS SQUIBB TO CO-DEVELOP DIGITAL THERAPEUTICS FOR ONCOLOGY New York, NY and Paris, France, 03 March 2020 Voluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY)

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome

Tue March 3, 2020 5:50 PM|Business Wire|About: ACAD

https://www.businesswire.com/news/home/20200303006075/en/

https://www.acadia-pharm.com/

https://www.acadia-pharm.com/pipeline/rett-syndrome/

https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-and-neuren-pharmaceuticals-announce-rare?field_nir_news_date_value[min]=

https://seekingalpha.com/symbol/ACAD

Trofinetide is a novel synthetic analog of the amino‐terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. ACADIA has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals.

Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics

ACADIA Pharma & Neuren Announce Rare Pediatric Disease Designation for Trofinetide for Rett Syndrome

Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19

Wed March 4, 2020 7:00 AM|Business Wire|About: ALNY, VIR

— Recent Alnylam (ALNY) advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses

— Vir to lead development of potential coronavirus RNAi therapeutic candidates, with Alnylam retaining an option for 50-50 participation

SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) and Alnylam Pharmaceuticals, Inc.

https://www.businesswire.com/news/home/20200304005363/en/

https://www.alnylam.com/

https://www.alnylam.com/alnylam-rnai-pipeline/

https://seekingalpha.com/symbol/ALNY

SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) =Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19 03/04/20 at 7:05 AM EST

BiotechVortex™

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Wed February 19, 2020 7:00 AM|Business Wire|About: DXCM, PODD

First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control
Initially compatible with Dexcom G6 CGM, with no fingersticks* required
Integration with the next generation Dexcom G7 CGM system, once available

SAN DIEGO & ACTON, Mass.--(BUSINESS WIRE)-- DexCom (DXCM), Inc. (NASDAQ: DXCM) and Insulet Corporation (PODD)

http://www.insulet.com/

https://www.myomnipod.com/home

https://www.businesswire.com/news/home/20200219005028/en/

https://seekingalpha.com/symbol/DXCM

https://seekingalpha.com/symbol/PODD

Discover the Dexcom G6 CGM System

BMS-986249

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Bristol-Myers study expansions triggers $10M payment to CytomX

Feb. 24, 2020 8:16 AM ET|About: CytomX Therapeutics, Inc. (CTMX)|By: Liz Kiesche, SA News Editor

https://cytomx.com/

https://cytomx.com/pipeline/

https://seekingalpha.com/symbol/CTMX

Our expanding pipeline of ProbodyTM therapeutics is built on a robust portfolio of proprietary and patented technology. Rooted in innovation and differentiation, and driven by our vision and mission, we are advancing a deep oncology pipeline of Probody therapeutics by blazing our own trail and in partnership with some of the world’s leading biopharmaceutical companies.

Heartline™

Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

Takeda Acquires PvP Biologics

Johnson & Johnson Launches Heartline™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke

Tue February 25, 2020 8:25 AM|PR Newswire|About: JNJ

Study aims to assess whether the Heartline Study app on iPhone, and the ECG app and irregular rhythm notification feature on Apple Watch, can reduce the likelihood of stroke and improve health outcomes with earlier detection of atrial fibrillation

PR Newswire

NEW BRUNSWICK, N.J., Feb. 25, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ)

https://www.heartline.com/

Johnson & Johnson Launches Heartline™, the First-of-Its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch can Help Reduce the Risk of Stroke

Johnson & Johnson, in collaboration with Apple, is offering eligible U.S. adults 65 years and older the opportunity to join the clinical study by downloading the Heartline Study app on iPhone

Study aims to assess whether the Heartline Study app on iPhone, and the ECG app and irregular rhythm notification feature on Apple Watch, can reduce the likelihood of stroke and improve health outcomes with earlier detection of atrial fibrillation

Heart Health Education Play Video

New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ)

https://www.multivu.com/players/English/8693251-heartline-study/

https://www.jnj.com/

https://www.prnewswire.com/news-releases/johnson--johnson-launches-heartline-the-first-of-its-kind-virtual-study-designed-to-explore-if-a-new-iphone-app-and-apple-watch-can-help-reduce-the-risk-of-stroke-301010792.html

Heartline™ =Johnson & Johnson, in collaboration with Apple, invites you to join the Heartline Study, a nationwide heart health research study for people 65+ with an iPhone. Receive heart health education and tips designed for people 65 and older Contribute to important medical research Eligible participants may earn compensation of $150+ for completing study activities*

Takeda Acquires PvP Biologics

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

Takeda Acquires PvP Biologics

Takeda Acquires PvP Biologics Following Results of a Phase 1 Study of TAK-062 (Kuma062) for the Treatment of Celiac Disease

Wed February 26, 2020 2:00 AM|Business Wire|About: TAK

− Investigational medicine TAK-062 is an oral computationally engineered super glutenase designed to improve the digestion of gluten

− Successful “build to buy” relationship adds second investigational therapy to Takeda’s pipeline for the potential treatment of uncontrolled celiac disease

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK)

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

October 22, 2019

https://www.takeda.com/newsroom/newsreleases/2019/takeda-acquires-license-for-first-in-class-celiac-disease-therapy-from--cour-pharmaceuticals-following-positive-phase-2a-proof-of-concept-study/

https://www.takeda.com/

https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/symptoms-causes

https://www.businesswire.com/news/home/20200225005816/en/

https://www.pvpbio.com/

https://seekingalpha.com/symbol/TAK

Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis

Wed February 26, 2020 8:30 AM|GlobeNewswire|About: AMGN, CYTK

Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes

Topline Results Expected in Q4 2020

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier

https://www.amgen.com/

https://cytokinetics.com/

https://servier.com/en/

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies

Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases

Thu February 27, 2020 4:06 PM|Business Wire|About: BIIB, SGMO

Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed neurological targets
Biogen will pay Sangamo $350 million upfront, including a license fee and an equity investment in Sangamo stock
Sangamo is eligible to receive up to $2.37 billion in potential milestones, as well as royalties on potential net commercial sales
Biogen’s access to Sangamo's gene regulation therapies complements its expanding efforts in gene therapy across diverse neurological diseases

CAMBRIDGE, Mass. & BRISBANE, Calif.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) and Sangamo Therapeutics, Inc. (SGMO),

https://www.businesswire.com/news/home/20200227005961/en/

Sangamo and Biogen Neurology Collaboration

February 27, 2020

https://investor.sangamo.com/static-files/81a67847-1710-4716-9e98-4fb798cbef8a

https://www.biogen.com/

https://www.sangamo.com/

https://seekingalpha.com/symbol/BIIB

https://seekingalpha.com/symbol/SGMO

Sangamo and Biogen Neurology Collaboration February 27, 2020

BiotechVortex™

Sanofi joins with U.S. Department of Health & Human Services to advance a novel coronavirus vaccine

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

Tue February 18, 2020 10:00 AM|GlobeNewswire|About: SNY

Sanofi (SNY) joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

*Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine

PARIS – February 18, 2020 – Sanofi Pasteur,

https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00